JP2015514771A - 神経保護性組成物および使用方法 - Google Patents

神経保護性組成物および使用方法 Download PDF

Info

Publication number
JP2015514771A
JP2015514771A JP2015507143A JP2015507143A JP2015514771A JP 2015514771 A JP2015514771 A JP 2015514771A JP 2015507143 A JP2015507143 A JP 2015507143A JP 2015507143 A JP2015507143 A JP 2015507143A JP 2015514771 A JP2015514771 A JP 2015514771A
Authority
JP
Japan
Prior art keywords
polyarginine
peptide
polyarginine peptide
arginine
cysteines
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015507143A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015514771A5 (enExample
Inventor
デニス ジェイ． ゴーベル，
デニス ジェイ． ゴーベル，
ジョン マーシャル，
ジョン マーシャル，
Original Assignee
ブラウン ユニバーシティ
ブラウン ユニバーシティ
ウェイン ステート ユニバーシティー
ウェイン ステート ユニバーシティー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ブラウン ユニバーシティ, ブラウン ユニバーシティ, ウェイン ステート ユニバーシティー, ウェイン ステート ユニバーシティー filed Critical ブラウン ユニバーシティ
Publication of JP2015514771A publication Critical patent/JP2015514771A/ja
Publication of JP2015514771A5 publication Critical patent/JP2015514771A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
    • C08G69/02—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids
    • C08G69/08—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids derived from amino-carboxylic acids
    • C08G69/10—Alpha-amino-carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Polymers & Plastics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
JP2015507143A 2012-04-17 2013-04-17 神経保護性組成物および使用方法 Pending JP2015514771A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261625349P 2012-04-17 2012-04-17
US61/625,349 2012-04-17
PCT/US2013/036938 WO2013158739A1 (en) 2012-04-17 2013-04-17 Neuroprotective composition and method of use

Publications (2)

Publication Number Publication Date
JP2015514771A true JP2015514771A (ja) 2015-05-21
JP2015514771A5 JP2015514771A5 (enExample) 2016-06-16

Family

ID=49384027

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015507143A Pending JP2015514771A (ja) 2012-04-17 2013-04-17 神経保護性組成物および使用方法

Country Status (6)

Country Link
US (2) US20150126457A1 (enExample)
EP (1) EP2872160A4 (enExample)
JP (1) JP2015514771A (enExample)
AU (1) AU2013249337A1 (enExample)
CA (1) CA2870711A1 (enExample)
WO (1) WO2013158739A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2872160A4 (en) 2012-04-17 2015-11-25 Univ Brown NERVO-PROTECTING COMPOSITION AND USE METHOD
CN106170491B (zh) * 2013-10-30 2020-07-24 阿尔杰妮卡治疗学有限公司 神经保护肽
US20170114093A1 (en) * 2015-05-29 2017-04-27 Andrew Peter Mallon Methods of Treatment and Prevention of Disease by Arginine-rich Compositions that Induce Cytoprotection and Neuroprotection
US20210101935A1 (en) 2019-10-02 2021-04-08 Brown University Cyclic peptidomimetic for the treatment of neurological disorders

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002502376A (ja) * 1997-05-21 2002-01-22 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ 生物学的膜を横切る輸送を増強するための組成物および方法
JP2007526316A (ja) * 2004-03-01 2007-09-13 ルーメン セラピューティックス リミテッド ライアビリティ カンパニー 疾患を処置するための組成物および方法
JP2010538006A (ja) * 2007-08-27 2010-12-09 カイ ファーマシューティカルズ インコーポレーティッド 細胞損傷および炎症から保護し、かつ星状細胞増殖を促進する、プロテインキナーゼＣ−δ阻害剤
WO2010150708A1 (ja) * 2009-06-22 2010-12-29 株式会社メディネット 蛋白質の修飾剤
WO2011026641A1 (en) * 2009-09-03 2011-03-10 Curevac Gmbh Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7229961B2 (en) * 1999-08-24 2007-06-12 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into ocular tissues
EP2459208B1 (en) * 2009-07-29 2016-09-28 Kai Pharmaceuticals, Inc. Therapeutic agents for reducing parathyroid hormone levels
EP2872160A4 (en) 2012-04-17 2015-11-25 Univ Brown NERVO-PROTECTING COMPOSITION AND USE METHOD

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002502376A (ja) * 1997-05-21 2002-01-22 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ 生物学的膜を横切る輸送を増強するための組成物および方法
JP2007526316A (ja) * 2004-03-01 2007-09-13 ルーメン セラピューティックス リミテッド ライアビリティ カンパニー 疾患を処置するための組成物および方法
JP2010538006A (ja) * 2007-08-27 2010-12-09 カイ ファーマシューティカルズ インコーポレーティッド 細胞損傷および炎症から保護し、かつ星状細胞増殖を促進する、プロテインキナーゼＣ−δ阻害剤
WO2010150708A1 (ja) * 2009-06-22 2010-12-29 株式会社メディネット 蛋白質の修飾剤
WO2011026641A1 (en) * 2009-09-03 2011-03-10 Curevac Gmbh Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids

Also Published As

Publication number Publication date
EP2872160A1 (en) 2015-05-20
EP2872160A4 (en) 2015-11-25
US20170107253A1 (en) 2017-04-20
WO2013158739A1 (en) 2013-10-24
AU2013249337A1 (en) 2014-10-30
CA2870711A1 (en) 2013-10-24
US20150126457A1 (en) 2015-05-07
US10040822B2 (en) 2018-08-07

Similar Documents

Publication Publication Date Title
US10406121B2 (en) Application of R-ketamine and salt thereof as pharmaceuticals
EP3615057B1 (en) Dosing regimen for treatment of cognitive impairments with blood plasma products
US11040068B2 (en) Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products
US20210283108A1 (en) Method for treating neurodegenerative diseases
KR20200143407A (ko) Cgrp를 억제하는데 사용하기 위한 신경독소
US12084491B2 (en) Treatment of Parkinson's disease
EP4374921A2 (en) Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products
CN116917482A (zh) 嵌合蛋白和治疗中枢神经系统疾病的方法
CN1711101A (zh) 孤独症及相似障碍的治疗
US10040822B2 (en) Neuroprotective composition and method of use
JP7609858B2 (ja) 脊髄損傷の治療のため及び／又は髄鞘再形成のためのペプチドの全身投与
RU2721282C2 (ru) Способ лечения рассеянного склероза (варианты)
US20230069856A1 (en) Blood Plasma Fractions for Improvement of Myelination
US20240058419A1 (en) Method for treating optic neuropathy
HK40112177A (en) Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products
Bang et al. Improvement of Lingual Dystonia Following Cerebellar Infarction through Botulinum Toxin Injection: a Case Report
AU2023378813A1 (en) Blood plasma fractions for improvement of myelination
EA051660B1 (ru) Способ лечения черепно-мозговой травмы и средство для его осуществления
WO2025023864A1 (ru) Способ лечения черепно-мозговой травмы и средство для его осуществления
JP2021534200A (ja) 脳損傷を回復させるための上皮成長因子と分泌促進物質ペプチドｇｈｒｐ６とを含む薬学的組合せ
NZ758615B2 (en) Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products
Shin Differential Glial Cell Responses in the Dentate Gyrus in Young Adult and Aged Brains Following Traumatic Brain Injury
Perera et al. in the vit tion. A
JP2019531329A (ja) 女性の性機能障害を治療する医薬組成物および方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141216

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160418

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160425

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20161222

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170814